CN109925495B - 一种用于治疗子宫腺肌病的中药组合物及其用途 - Google Patents
一种用于治疗子宫腺肌病的中药组合物及其用途 Download PDFInfo
- Publication number
- CN109925495B CN109925495B CN201910269611.9A CN201910269611A CN109925495B CN 109925495 B CN109925495 B CN 109925495B CN 201910269611 A CN201910269611 A CN 201910269611A CN 109925495 B CN109925495 B CN 109925495B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- adenomyosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 201000009274 endometriosis of uterus Diseases 0.000 title claims abstract description 31
- 208000005641 Adenomyosis Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 23
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 23
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 23
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 22
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 22
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 21
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 20
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 20
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 20
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 20
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 20
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 20
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 20
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 235000008397 ginger Nutrition 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- 235000013976 turmeric Nutrition 0.000 claims abstract description 20
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 19
- 241000287828 Gallus gallus Species 0.000 claims abstract description 14
- 239000012528 membrane Substances 0.000 claims abstract description 14
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 208000005171 Dysmenorrhea Diseases 0.000 claims abstract description 8
- 208000000450 Pelvic Pain Diseases 0.000 claims abstract description 7
- 208000007106 menorrhagia Diseases 0.000 claims abstract description 4
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 244000150195 Cyperus longus Species 0.000 claims description 2
- 235000018109 Cyperus longus Nutrition 0.000 claims description 2
- 244000075634 Cyperus rotundus Species 0.000 claims description 2
- 235000005010 Scirpus paludosus Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 37
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000010792 warming Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 28
- 238000000034 method Methods 0.000 description 18
- 241001106477 Paeoniaceae Species 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000234314 Zingiber Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000004291 uterus Anatomy 0.000 description 12
- 210000003038 endothelium Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 6
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 102000006771 Gonadotropins Human genes 0.000 description 4
- 108010086677 Gonadotropins Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 239000002622 gonadotropin Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 235000014375 Curcuma Nutrition 0.000 description 3
- 240000009138 Curcuma zedoaria Species 0.000 description 3
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 210000000754 myometrium Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 239000001917 trigonella foenum graecum l. absolute Substances 0.000 description 3
- 235000019509 white turmeric Nutrition 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229960004761 gestrinone Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000016117 decidualization Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000685 uterine artery Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910269611.9A CN109925495B (zh) | 2019-04-04 | 2019-04-04 | 一种用于治疗子宫腺肌病的中药组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910269611.9A CN109925495B (zh) | 2019-04-04 | 2019-04-04 | 一种用于治疗子宫腺肌病的中药组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109925495A CN109925495A (zh) | 2019-06-25 |
CN109925495B true CN109925495B (zh) | 2021-06-15 |
Family
ID=66989170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910269611.9A Active CN109925495B (zh) | 2019-04-04 | 2019-04-04 | 一种用于治疗子宫腺肌病的中药组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109925495B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264270A (zh) * | 2008-04-25 | 2008-09-17 | 北京和润创新医药科技发展有限公司 | 一种治疗子宫内膜异位症的中药组合物及其制备方法 |
-
2019
- 2019-04-04 CN CN201910269611.9A patent/CN109925495B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264270A (zh) * | 2008-04-25 | 2008-09-17 | 北京和润创新医药科技发展有限公司 | 一种治疗子宫内膜异位症的中药组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
活血消异方治疗子宫内膜异位症的临床观察及实验研究;李田田;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20170215;第2017年卷(第2期);E056-1432 * |
温阳活血汤加减治疗子宫腺肌病相关疼痛的临床观察;李伟华 等;《中华中医药杂志(原中国医药学报)》;20181130;第33卷(第11期);第5267-5270页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109925495A (zh) | 2019-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Treating gynaecological disorders with traditional Chinese medicine: a review | |
CN101780160B (zh) | 一种治疗妇科疾病的中药制剂及其制备方法 | |
CN100446806C (zh) | 新生化口服液及其制备方法 | |
Jiang et al. | Treatment of Chinese herbal medicine for female infertility | |
CN106334060B (zh) | 一种治疗肥胖型多囊卵巢综合征的药物组合物 | |
CN102973677B (zh) | 一种治疗卵巢囊肿的中药 | |
CN102861148B (zh) | 一种治疗原发性痛经的中药制剂及制备方法与应用 | |
CN104491736A (zh) | 一种治疗乳腺增生的中药组合物及其制备方法 | |
CN109925495B (zh) | 一种用于治疗子宫腺肌病的中药组合物及其用途 | |
CN100391494C (zh) | 一种治疗痛证的中药复方制剂及其制备方法 | |
CN103142902B (zh) | 治疗乳腺增生疾病的中药组合物和制剂及其制备方法 | |
JPH11139980A (ja) | 潰瘍性大腸炎治療剤 | |
CN105012379A (zh) | 一种治疗输卵管阻塞不孕的中药组合物 | |
CN111298092B (zh) | 一种治疗继发性痛经的中药 | |
AU2021104182A4 (en) | Traditional Chinese medicine composition for treating chronic pelvic pain and dysmenorrhea caused by endometriosis | |
CN112022988B (zh) | 一种具有预防和/或治疗痛经作用的中药组合物及其制备方法和应用 | |
CN109432115B (zh) | 一种治疗原发性痛经的药物及其用途 | |
CN108420855B (zh) | 一种防治痛经的药物组合物 | |
CN106798864B (zh) | 一种治疗内异症的中药组合物 | |
CN105770753A (zh) | 一种治疗宫外孕的中药组合物 | |
CN105998579A (zh) | 一种治疗输卵管炎性不孕症的药物及其制备方法和应用 | |
CN103638452B (zh) | 用于治疗输卵管积水的药物组合物及其制备方法 | |
CN105250952B (zh) | 一种治疗子宫腺肌症的中药组合物 | |
Li et al. | A systematic review of the mechanistic actions of microRNAs within integrated traditional Chinese medicine and western medical treatment for endometriosis | |
CN104547786A (zh) | 治疗高雄激素性痤疮的外用中药组合物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230605 Address after: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: No. 5, North Line Pavilion, Xicheng District, Beijing 100053 Patentee before: GUANG'ANMEN HOSPITAL, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240425 Address after: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Country or region after: China Patentee after: Tianjin Tasly Modern TCM Resources Co.,Ltd. Address before: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Country or region before: China |